Literature DB >> 1721011

Antibodies to mouse laminin in patients with systemic sclerosis (scleroderma) recognize galactosyl (alpha 1-3)-galactose epitopes.

A Gabrielli1, M Candela, A M Ricciatti, M L Caniglia, J Wieslander.   

Abstract

Employing radioimmunoinhibition assays with distinct oligosaccharides as inhibitors, this study demonstrates that the epitope recognized on mouse laminin by sera from patients with systemic sclerosis (scleroderma) is a terminal galactosyl (alpha 1-3)-galactose disaccharide. The reaction with this alpha-digalactose was further confirmed when the sera were tested in radioimmunoassay (RIA) binding assay and in ELISA with synthetic galactose alpha 1-3 galactose coupled to human serum albumin. The circulating antibody appeared restricted to the IgG class and mostly to the subclass IgG3 and IgG4. Antibodies with the same specificity can be found in patients with American cutaneous leishmaniasis and Chagas disease; however, whilst in these diseases the antibody production is triggered by antigenic determinants present on the surface of the parasites, the events eliciting their appearance in systemic sclerosis are unknown.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721011      PMCID: PMC1554213          DOI: 10.1111/j.1365-2249.1991.tb02939.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Ultrastructure of cutaneous cellular infiltrates in scleroderma.

Authors:  R Fleischmajer; J S Perlish; W P West
Journal:  Arch Dermatol       Date:  1977-12

2.  Excessive binding of natural anti-alpha-galactosyl immunoglobin G to sickle erythrocytes may contribute to extravascular cell destruction.

Authors:  U Galili; M R Clark; S B Shohet
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

3.  A retrospective study of antibodies against basement membrane antigens (type IV collagen and laminin) in patients with primary and secondary Raynaud's phenomenon.

Authors:  A Gabrielli; M Montroni; S Rupoli; M L Caniglia; F DeLustro; G Danieli
Journal:  Arthritis Rheum       Date:  1988-11

Review 4.  Antibodies to collagens and procollagens.

Authors:  R Timpl
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

5.  Antibodies to laminin in American cutaneous leishmaniasis.

Authors:  J L Avila; M Rojas; M Rieber
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

6.  Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis.

Authors:  C A Penning; J Cunningham; M A French; G Harrison; N R Rowell; P Hughes
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

7.  Cellular immunity to collagen and laminin in scleroderma.

Authors:  J E Huffstutter; F A DeLustro; E C LeRoy
Journal:  Arthritis Rheum       Date:  1985-07

8.  Antibodies to collagen in scleroderma.

Authors:  A M Mackel; F DeLustro; F E Harper; E C LeRoy
Journal:  Arthritis Rheum       Date:  1982-05

9.  Possible role of human natural anti-Gal antibodies in the natural antitumor defense system.

Authors:  V Castronovo; C Colin; B Parent; J M Foidart; R Lambotte; P Mahieu
Journal:  J Natl Cancer Inst       Date:  1989-02-01       Impact factor: 13.506

10.  Antibodies to laminin in Chagas' disease.

Authors:  A Szarfman; V P Terranova; S I Rennard; J M Foidart; M de Fatima Lima; J I Scheinman; G R Martin
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Immune response to biologic scaffold materials.

Authors:  Stephen F Badylak; Thomas W Gilbert
Journal:  Semin Immunol       Date:  2008-02-20       Impact factor: 11.130

2.  Simple radioimmunological assay of anti-alpha-galactosyl antibody (anti-Gal): application to autoimmune thyroid diseases and thyroid-associated ophthalmopathy.

Authors:  R J Winand; J Winand-Devigne; C Cox; C Caulier; M Meurisse
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

3.  Anti-laminin autoantibodies in collagen vascular diseases: the use of adequate controls in studies of autoimmune responses to laminin.

Authors:  D E Cohen; L D Kaufman; A A Varma; J R Seibold; M Stiller; B L Gruber
Journal:  Ann Rheum Dis       Date:  1994-03       Impact factor: 19.103

Review 4.  Proper animal experimental designs for preclinical research of biomaterials for intervertebral disc regeneration.

Authors:  Yizhong Peng; Xiangcheng Qing; Hongyang Shu; Shuo Tian; Wenbo Yang; Songfeng Chen; Hui Lin; Xiao Lv; Lei Zhao; Xi Chen; Feifei Pu; Donghua Huang; Xu Cao; Zengwu Shao
Journal:  Biomater Transl       Date:  2021-06-28

5.  Laminin-521 is a Novel Target of Autoantibodies Associated with Lung Hemorrhage in Anti-GBM Disease.

Authors:  Cong-Rong Shen; Xiao-Yu Jia; Wentian Luo; Florina Olaru; Zhao Cui; Ming-Hui Zhao; Dorin-Bogdan Borza
Journal:  J Am Soc Nephrol       Date:  2021-04-23       Impact factor: 14.978

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.